Y mAbs Therapeutics (YMAB) — Cash Flow Reinvestment Rate
Latest as of June 2025:
0.00x
Y mAbs Therapeutics (YMAB) has a Cash Flow Reinvestment Rate of 0.00x as of June 2025, reinvesting $0.00 (capex $0.00 ) from operating cash flow of $1.65 Million. See YMAB net asset quality index to measure how much of total assets are equity-financed.
Reinvestment Rate
0.00x
(Capex + Investments) / Operating CF
Total Reinvested
$0.00
Capex + Investments
Operating Cash Flow
$1.65 Million
USD
Capital Expenditures
$0.00
USD
Annual Cash Flow Reinvestment Rate for Y mAbs Therapeutics (None–None)
Year-by-year capital reinvestment analysis for Y mAbs Therapeutics. For live market cap and broader valuation context, see YMAB market cap overview.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow